Our nation's over-dependence on foreign pharmaceutical production has left America vulnerable. The Covid-19 pandemic revealed that the U.S. is dangerously exposed to supply chain disruptions. Our limited domestic manufacturing capabilities of lifesaving medicines is a...
Bright Path Labs chosen as a collaborator in a first-ever National Science Foundation Engines Award
Bright Path Labs chosen as a collaborator in a first-ever National Science Foundation Engines AwardBright Path is proud to have been chosen to collaborate with the The Puerto Rico Science, Technology, & Research Trust in a $1M NSF Innovation Engines Development...
Bright Path Labs is proud to announce its admittance to the Green Chemistry and Commerce Council (GC3)! We are eager to learn from and collaborate with leaders in sustainable and green technologies across different sectors. Our technology and approach are deeply...
Supply chain disruption will be with biopharmaceutical companies for the foreseeable future, according to the recent CFO survey, Supply Chain Resilience, by BDO. A separate report by Catalent, Allogeneic and Autologous Cell Therapies Report 2022, agrees, saying,...
Tony Quinones, CEO of Bright Path Laboratories, discusses the latest on the omicron variant and Covid vaccines with Bryan Curtis and Paul Allen on Bloomberg Daybreak Asia.
Bright Path CEO Tony Quinone joins Yahoo Finance to discuss how the Build Back Better Plan will promote locally produced pharmaceutical drugs.
Vice-Chairman of the Coalition for a Prosperous America. Bright Path Labs has appointed Mr. Marc Fasteau as an independent director. Tony Quinones, CEO of BPL, stated, "We are extraordinarily honored and pleased that Mr. Fasteau has elected to join our board as an...
Bright Path Labs has a technology that brings speed to the commercialization of API production. Continuous manufacturing is a big need in the pharmaceutical sector and Bright Path lab's technology accelerates that process. In order to enable and commercialize the...